Drugs / Envolimab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07000305 | May 2025 → May 2027 expected | colorectal cancer | Tao Zhang | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05914610 | Sep 2023 → Jul 2025 overdue | gastric cancer | Fujian Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Envolimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07000305 ↗ |
| Route | Subcutaneous | “200 mg, sc, day 1” NCT07000305 ↗ |